Quinism

Quinism

Quinism is a medical condition primarily associated with the chronic neurotoxic effects of mefloquine, an antimalarial medication. This condition is characterized by a range of symptoms including tinnitus, dizziness, vertigo, paresthesias, visual disturbances, and neuropsychiatric symptoms such as anxiety, depression, and psychosis. The term "quinism" is derived from quinine, the natural predecessor of mefloquine, which has been used for centuries to treat malaria and is known to cause similar side effects in some individuals.

Symptoms and Diagnosis

The symptoms of quinism can vary widely among individuals but generally involve a combination of neurological and psychiatric manifestations. Neurological symptoms often include tinnitus, dizziness, vertigo, and paresthesias (abnormal skin sensations such as tingling, pricking, or numbness). Psychiatric symptoms may encompass anxiety, depression, psychosis, and cognitive disturbances. Diagnosis of quinism is primarily clinical, based on the patient's history of mefloquine use and the presence of characteristic symptoms. There are no specific laboratory tests for quinism, making diagnosis challenging.

Treatment and Management

Management of quinism focuses on symptom relief and may involve the use of medications to treat specific symptoms such as antidepressants for depression or antipsychotics for psychosis. In some cases, cessation of mefloquine may lead to improvement of symptoms, although for many individuals, symptoms may persist long-term. Supportive therapies, including counseling and cognitive-behavioral therapy, may be beneficial for managing the psychiatric symptoms associated with quinism.

Epidemiology

Quinism is most commonly reported among travelers, military personnel, and others who have used mefloquine as prophylaxis or treatment for malaria. The exact prevalence of quinism is difficult to determine due to underreporting and the lack of specific diagnostic criteria.

History

The association between mefloquine and neurotoxic effects was first recognized in the late 20th century, following the introduction of mefloquine in the 1980s as an antimalarial drug. Over time, increasing reports of adverse neuropsychiatric effects in individuals taking mefloquine led to the identification of quinism as a distinct medical condition.

Controversies and Research

There has been ongoing controversy regarding the safety of mefloquine and the recognition of quinism as a medical condition. Some researchers and healthcare professionals argue that the risks associated with mefloquine are underrecognized and that quinism should be more widely acknowledged and researched. Efforts are ongoing to better understand the pathophysiology of quinism and to develop more effective treatments for those affected.